WCN26-5897 DIFELIKEFALIN USE IN HAEMODIALYSIS RECIPIENTS WITH GABAPENTINOID-REFRACTORY CHRONIC KIDNEY DISEASE ASSOCIATED PRURITUS

Read full text Summarise with VIRAT
Authors: Kelly Chenlei Li, Alison Smyth
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Chronic kidney disease associated pruritus (CKDaP) is common in individuals receiving chronic haemodialysis, and severe itch can adversely impact sleep and quality of life. Difelikefalin is a kappa-opioid receptor agonist indicated for the treatment of moderate to severe CKDaP and reported to improve itch and quality of life. Most patients enrolled in existing studies of difelikefalin have not received treatment with gabapentinoids, the only class of medication previously found to be highly efficacious in CKDaP, and no head-to-head comparisons exist between the two classes of pharmacotherapy.

Fields of Study & Subjects

Dialysis and Renal Disease Management Dermatology and Skin Diseases Chronic Kidney Disease and Diabetes

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104126–104126
Publication date
25 March 2026
Language
EN